Sales Growth YoY (Last 12 Months): Novo Nordisk A/S (NVO)

Scaling plants in Europe and the US supports colossal demand for Wegovy and Ozempic. The year-over-year sales growth percentage for TTM visualizes this expansion, where the value of 11.00 expresses the metric level. Revenue stability is based on the regular consumption of diabetes medications, which guarantees Novo Nordisk A/S (NVO) a predictable financial result and high business resilience.
Novo Nordisk - analytical breakdowns and key metrics (NVO)

This indicator determines the revenue growth rate over a rolling year, excluding seasonal anomalies to provide an objective assessment of business scaling. Analyzing the rolling 12-month sales dynamics versus the same period last year allows for a comparison of financial results with the expansion of Novo Nordisk A/S (NVO) in the diabetes and obesity segments, where synergy from the acquisition of new technological platforms directly converts into accelerated operational growth.